TY - JOUR
T1 - Sleep Apnea Syndrome (SAS) Clinical Practice Guidelines 2020
AU - Akashiba, Tsuneto
AU - Inoue, Yuichi
AU - Uchimura, Naohisa
AU - Ohi, Motoharu
AU - Kasai, Takatoshi
AU - Kawana, Fusae
AU - Sakurai, Shigeru
AU - Takegami, Misa
AU - Tachikawa, Rho
AU - Tanigawa, Takeshi
AU - Chiba, Shintaro
AU - Chin, Kazuo
AU - Tsuiki, Satoru
AU - Tonogi, Morio
AU - Nakamura, Hiroshi
AU - Nakayama, Takeo
AU - Narui, Koji
AU - Yagi, Tomoko
AU - Yamauchi, Motoo
AU - Yamashiro, Yoshihiro
AU - Yoshida, Masahiro
AU - Oga, Toru
AU - Tomita, Yasuhiro
AU - Hamada, Satoshi
AU - Murase, Kimihiko
AU - Mori, Hiroyuki
AU - Wada, Hiroo
AU - Uchiyama, Makoto
AU - Ogawa, Hiromasa
AU - Sato, Kazumichi
AU - Nakata, Seiichi
AU - Mishima, Kazuo
AU - Momomura, Shin Ichi
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2022/1
Y1 - 2022/1
N2 - The prevalence of sleep disordered breathing (SDB) is reportedly very high. Among SDBs, the incidence of obstructive sleep apnea (OSA) is higher than previously believed, with patients having moderate-to-severe OSA accounting for approximately 20% of adult males and 10% of postmenopausal women not only in Western countries but also in Eastern countries, including Japan. Since 1998, when health insurance coverage became available, the number of patients using continuous positive airway pressure (CPAP) therapy for sleep apnea has increased sharply, with the number of patients about to exceed 500,000 in Japan. Although the “Guidelines for Diagnosis and Treatment of Sleep Apnea Syndrome (SAS) in Adults” was published in 2005, a new guideline was prepared in order to indicate the standard medical care based on the latest trends, as supervised by and in cooperation with the Japanese Respiratory Society and the “Survey and Research on Refractory Respiratory Diseases and Pulmonary Hypertension” Group, of Ministry of Health, Labor and Welfare and other related academic societies, including the Japanese Society of Sleep Research, in addition to referring to the previous guidelines. Because sleep apnea is an interdisciplinary field covering many areas, this guideline was prepared including 36 clinical questions (CQs). In the English version, therapies and managements for SAS, which were written from CQ16 to 36, were shown. The Japanese version was published in July 2020 and permitted as well as published as one of the Medical Information Network Distribution Service (Minds) clinical practice guidelines in Japan in July 2021.
AB - The prevalence of sleep disordered breathing (SDB) is reportedly very high. Among SDBs, the incidence of obstructive sleep apnea (OSA) is higher than previously believed, with patients having moderate-to-severe OSA accounting for approximately 20% of adult males and 10% of postmenopausal women not only in Western countries but also in Eastern countries, including Japan. Since 1998, when health insurance coverage became available, the number of patients using continuous positive airway pressure (CPAP) therapy for sleep apnea has increased sharply, with the number of patients about to exceed 500,000 in Japan. Although the “Guidelines for Diagnosis and Treatment of Sleep Apnea Syndrome (SAS) in Adults” was published in 2005, a new guideline was prepared in order to indicate the standard medical care based on the latest trends, as supervised by and in cooperation with the Japanese Respiratory Society and the “Survey and Research on Refractory Respiratory Diseases and Pulmonary Hypertension” Group, of Ministry of Health, Labor and Welfare and other related academic societies, including the Japanese Society of Sleep Research, in addition to referring to the previous guidelines. Because sleep apnea is an interdisciplinary field covering many areas, this guideline was prepared including 36 clinical questions (CQs). In the English version, therapies and managements for SAS, which were written from CQ16 to 36, were shown. The Japanese version was published in July 2020 and permitted as well as published as one of the Medical Information Network Distribution Service (Minds) clinical practice guidelines in Japan in July 2021.
UR - http://www.scopus.com/inward/record.url?scp=85121625385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121625385&partnerID=8YFLogxK
U2 - 10.1016/j.resinv.2021.08.010
DO - 10.1016/j.resinv.2021.08.010
M3 - Article
C2 - 34986992
AN - SCOPUS:85121625385
SN - 2212-5345
VL - 60
SP - 3
EP - 32
JO - Respiratory Investigation
JF - Respiratory Investigation
IS - 1
ER -